Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
Liver transplantation (LT) is a well-established treatment for hepatocellular carcinoma (HCC) in carefully selected patients. Risk factors for tumors with poor prognostic features on explant have not been well described in a national cohort. We performed a retrospective cohort study of adult LT recipients with HCC transplanted from April 8, 2012 (when explant pathology in United Network for Organ Sharing [UNOS] became available) until September 30, 2014. We evaluated the association between listing diagnosis and other demographic factors with tumor features on explant using logistic regression. High-risk tumor features included the following: > 3 tumors, largest tumor > 5 cm, presence of vascular invasion, presence of metastases, and poor differentiation of tumor. In total, 3733 LT recipients with HCC who had complete explant data in UNOS were included. The median age was 60 years; 78% were male; and 68% were white. Of the primary non-HCC listing diagnoses, 2608 (70%) had hepatitis C virus (HCV); 271 (7%) had nonalcoholic steatohepatitis (NASH); 246 (7%) had alcoholic cirrhosis; and 189 (5%) had hepatitis B virus. Also, 1140 (31%) had evidence of ≥ 1 high-risk explant feature(s). The presence of ≥ 1 high-risk explant feature(s) was associated with HCC recurrence after transplant (odds ratio [OR], 5.00; P < 0.001). Compared with HCV-associated HCC transplant recipients, individuals with NASH had lower likelihood of high-risk explant features (OR, 0.71; P = 0.02) after adjusting for covariables. Women were more likely to have high-risk explant features (OR, 1.23; P = 0.04). Diabetes mellitus (DM) was not associated with high-risk explant features. In conclusion, LT recipients with NASH-associated HCC had fewer high-risk tumor features on explant compared with HCV-associated HCC, despite having higher rates of DM and other potential risk factors for the development of HCC. Women had a higher likelihood of high-risk tumor features. Further study is warranted whether these differences are due to disease-specific or sex-specific influences on tumor biology or due to selection criteria for transplant. Liver Transplantation 23 1015-1022 2017 AASLD.
Department of Medicine, Divisions of Gastroenterology, University of California, San Francisco, San Francisco, CA.
Sara M
SM
Lewin
Department of Medicine, Divisions of Gastroenterology, University of California, San Francisco, San Francisco, CA.
Neil
N
Mehta
Hematology/Oncology, University of California, San Francisco, San Francisco, CA.
R Kate
RK
Kelley
Department of Surgery, University of California, San Francisco, San Francisco, CA.
John P
JP
Roberts
Department of Medicine, Divisions of Gastroenterology, University of California, San Francisco, San Francisco, CA.
Francis Y
FY
Yao
Department of Medicine, Divisions of Gastroenterology, University of California, San Francisco, San Francisco, CA.
Danielle
D
Brandman
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery / Q000821:virology; D015897:Comorbidity; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D006515:Hepatitis B virus / Q000302:isolation & purification; D006801:Humans; D008099:Liver / Q000473:pathology / Q000601:surgery / Q000821:virology; D008104:Liver Cirrhosis, Alcoholic / Q000453:epidemiology / Q000473:pathology / Q000601:surgery; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D065626:Non-alcoholic Fatty Liver Disease / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D018579:Patient Selection; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D066027:Transplant Recipients / Q000706:statistics & numerical data